Experimentally designed, validated hplc simultaneous determination of pridinol and diclofenac in their combined pharmaceutical formulations, which allows limiting diclofenac related compound A
The development and validation of an HPLC method for the determination of pridinol and diclofenac in their combined formulations and the simultaneous limit testing of diclofenac related compound A is described. The separation was performed on a C18 column. Experimental design and response surface st...
| Autores: | , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2010 |
| País: | Argentina |
| Institución: | Consejo Nacional de Investigaciones Científicas y Técnicas |
| Repositorio: | CONICET Digital (CONICET) |
| Idioma: | inglés |
| OAI Identifier: | oai:ri.conicet.gov.ar:11336/133263 |
| Acceso en línea: | http://hdl.handle.net/11336/133263 |
| Access Level: | acceso abierto |
| Palabra clave: | DICLOFENAC DICLOFENAC RELATED COMPOUND A EXPERIMENTAL DESIGN HPLC DETERMINATION PRIDINOL VALIDATION https://purl.org/becyt/ford/1.4 https://purl.org/becyt/ford/1 |
| Sumario: | The development and validation of an HPLC method for the determination of pridinol and diclofenac in their combined formulations and the simultaneous limit testing of diclofenac related compound A is described. The separation was performed on a C18 column. Experimental design and response surface strategies were employed for optimizing detection wavelength (225nm) and mobile phase composition [MeOH:2-propanol:phosphate buffer (50mM, pH 5.5), 48:9:43 (v/v/v), 1mLmin-1], and for validation purposes. The method was successfully applied to the quality control of commercial brands of tablets and capsules. Found impurity levels were below 0.1% (LOQ=0.02%). Stressed samples were also evaluated. |
|---|